Genomics

Dataset Information

0

Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [ChIP-Seq]


ABSTRACT: The majority of BRAFV600 mutant melanomas regress in response to BRAF/MEK inhibitors (BRAFi/MEKi). Yet nearly all relapse within the first two years. Most BRAFi/MEKi-resistant tumors are cross-resistant to immunotherapies, highlighting the need to prevent and circumvent resistance. We recently showed that androgen receptor (AR) activity is required for sustained melanoma cells proliferation and tumorigenesis. Here we find that AR expression is markedly increased in BRAFi resistant melanoma cells as well as in sensitive cells already at very early times of BRAFi exposure. Proliferation and tumorigenicity of BRAFi resistant melanoma cells are blunted by genetic or pharmacologic suppression of AR activity, while AR overexpression is by itself sufficient to rendersmelanoma cells BRAFi/MEKi-resistant. Increased AR elicits transcriptional changes linked with AXL-positive BRAFi resistant subpopulations and induces expression of PAI-1 and EGFR, two determinants of melanoma progression that associate with elevated AR expression in clinical cohorts. Our results point to increased AR signaling as a determinant of melanoma BRAFi resistance, which can be counteracted by AR as well as PAI-1 and EGFR inhibitors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE232690 | GEO | 2023/08/03

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-08-03 | GSE232693 | GEO
2023-08-03 | GSE199405 | GEO
2021-12-01 | GSE186108 | GEO
2020-02-27 | GSE145990 | GEO
2023-11-14 | GSE245262 | GEO
2023-10-30 | GSE239284 | GEO
2022-01-24 | GSE180568 | GEO
2019-01-31 | GSE114488 | GEO
2024-06-01 | PXD052251 | Pride
2024-06-01 | PXD052259 | Pride